{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:35:36Z","timestamp":1790400936203,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Octapharma AG","award":["NCT01012323"],"award-info":[{"award-number":["NCT01012323"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejps.2018.03.007","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T18:37:47Z","timestamp":1520361467000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study"],"prefix":"10.1016","volume":"118","author":[{"given":"Isaac R.","family":"Melamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenz","family":"Trawnicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Lan","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger H.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Knutsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pituch-Noworolska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Strach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazyna","family":"Pulka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans D.","family":"Ochs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.03.007_bb0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1423-0410.2003.00286.x","article-title":"Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%)","volume":"84","author":"Ballow","year":"2003","journal-title":"Vox Sang."},{"key":"10.1016\/j.ejps.2018.03.007_bb0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10875-009-9348-y","article-title":"Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency","volume":"30","author":"Berger","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"Berger","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1423-0410.2006.00764.x","article-title":"Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia","volume":"90","author":"Bjorkander","year":"2006","journal-title":"Vox Sang."},{"key":"10.1016\/j.ejps.2018.03.007_bb0025","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1445-5994.2011.02712.x","article-title":"Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies","volume":"42","author":"Bleasel","year":"2012","journal-title":"Intern. Med. J."},{"issue":"Suppl. 2","key":"10.1016\/j.ejps.2018.03.007_bb0030","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1007\/s10875-012-9838-1","article-title":"Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease","volume":"33","author":"Bonagura","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.ejps.2018.03.007_bb0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10875-017-0424-4","article-title":"Efficacy and safety of human intravenous immunoglobulin 10% (panzyga\u00ae) in patients with primary immunodeficiency diseases: a two-stage, multicentre, prospective, open-label study","volume":"37","author":"Borte","year":"2017","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0045","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-006-9025-3","article-title":"Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency","volume":"26","author":"Church","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nri3466","article-title":"Primary antibody deficiencies","volume":"13","author":"Durandy","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0055","author":"European Medicines Agency"},{"key":"10.1016\/j.ejps.2018.03.007_bb0060","author":"Food and Drug Administration, Center for Biologics Evaluation and Research (CBER)"},{"key":"10.1016\/j.ejps.2018.03.007_bb0065","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.iac.2008.07.001","article-title":"Immunoglobulin replacement therapy in children","volume":"28","author":"Garcia-Lloret","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.ejps.2018.03.007_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u2013a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2015.11.004","article-title":"The crossroads of autoimmunity and immunodeficiency: lessons from polygenic traits and monogenic defects","volume":"137","author":"Grimbacher","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","article-title":"Efficacy and safety of Hizentra ((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy","volume":"141","author":"Jolles","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0085","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3389\/fimmu.2014.00690","article-title":"Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects","volume":"5","author":"Matucci","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2172-15-26","article-title":"Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study","volume":"15","author":"Nobre","year":"2014","journal-title":"BMC Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10875-017-0464-9","article-title":"Primary immunodeficiency diseases committee report on inborn errors of immunity","volume":"38","author":"Picard","year":"2018","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0110","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","article-title":"High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease","volume":"1","author":"Roifman","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2018.03.007_bb0115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-016-0243-z","article-title":"Quantitative evidence of wear-off effect at the end of the intravenous IgG (IVIG) dosing cycle in primary immunodeficiency","volume":"36","author":"Rojavin","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s15010-012-0323-9","article-title":"Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients","volume":"40","author":"Schroeder","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.ejps.2018.03.007_bb0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3810\/pgm.2010.09.2214","article-title":"The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins","volume":"122","author":"Stein","year":"2010","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejps.2018.03.007_bb0135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/1744666X.2014.891438","article-title":"A new intravenous immunoglobulin (BIVIGAM\u00ae) for primary humoral immunodeficiency","volume":"10","author":"Wasserman","year":"2014","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0140","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejps.2009.02.014","article-title":"Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency","volume":"37","author":"Wasserman","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.03.007_bb0145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2249.2010.04195.x","article-title":"Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate\/chromatography purified in patients with primary immunodeficiency disease","volume":"161","author":"Wasserman","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10875-011-9512-z","article-title":"Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease","volume":"31","author":"Wasserman","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","article-title":"Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency","volume":"50","author":"Wasserman","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.03.007_bb0160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-012-9656-5","article-title":"Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency","volume":"32","author":"Wasserman","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0165","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","article-title":"Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency","volume":"36","author":"Wasserman","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejps.2018.03.007_bb0170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TCRM.S22599","article-title":"Human normal immunoglobulin in the treatment of primary immunodeficiency diseases","volume":"8","author":"Wood","year":"2012","journal-title":"Ther. Clin. Risk Manag."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718301222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718301222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T13:51:24Z","timestamp":1549893084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718301222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":34,"alternative-id":["S0928098718301222"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.03.007","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}